Donor Login
Contact Us
Breakthrough T1D
About
Investment Strategy
Portfolio
Our Team
Venture Philanthropy
News
Donor Login
Get in Touch
News and Press
Mozart Therapeutics Completes Ph1a Study in Healthy Adults; Data Shows MTX-101 is Well Tolerated and Selectively Activates CD8 Treg
March 17, 2025
Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer
January 15, 2025 |
Paris, France
The T1D Fund Appoints Industry Veteran Elizabeth Mily as CEO to Accelerate Development of Type 1 Diabetes Cures Through Impact Investing
January 08, 2025 |
BOSTON, Mass.
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
January 08, 2025
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
January 07, 2025
